← Leaderboards
Yun Shin Chun
Sloan-Kettering Inst Can Research
$1,158,484
Attributed
$3,475,451
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $744.1K · FY2019–23$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,475,451 · 1
By mechanism
R01$3,475,451 · 1
Top collaborators
- Richard Kinh Gian Do5 shared
- Amber Simpson5 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Jason S Lewis$26,024,327
- Isabelle Riviere$12,156,024
- Raymond J Muller$2,385,467
- Pankaj Chaturvedi$1,198,588
- Timothy An-Thy Chan$21,076,830
Others in their field
Other Emerging Leaders on “Diagnostic”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$293,634,608
- Lynn Briscoe · Leidos Biomedical Research, Inc.$100,239,656
- Leonard Freedmand · Leidos Biomedical Research, Inc.$63,918,621
- Mark Marino · Venturewell$61,502,138
- Scott Topper · Broad Institute, Inc.$51,811,587
Research focus
DiagnosticAffectAlgorithmsDesignBiometryCancer CareCancer CenterCancer DiagnosisCancer EtiologyDecision MakingCessation Of LifeChemotherapyClinical CareClinical TrialsCollaborationsColon Cancer PatientsColorectalColorectal CancerComparativeComputer SoftwareCostData SetConvolutional Neural NetworkDisease Progression
Grant awards (5)
Development and Validation of Prognostic Radiomic Markers of Response and Recurrence for Patients with Colorectal Liver Metastases$659,173
R01 · FY2023 · CA
Development and Validation of Prognostic Radiomic Markers of Response and Recurrence for Patients with Colorectal Liver Metastases$683,138
R01 · FY2022 · CA
Development and Validation of Prognostic Radiomic Markers of Response and Recurrence for Patients with Colorectal Liver Metastases$690,882
R01 · FY2021 · CA
Development and Validation of Prognostic Radiomic Markers of Response and Recurrence for Patients with Colorectal Liver Metastases$698,152
R01 · FY2020 · CA
Development and Validation of Prognostic Radiomic Markers of Response and Recurrence for Patients with Colorectal Liver Metastases$744,106
R01 · FY2019 · CA